Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

In addition to these capital structure changes, Silexion Therapeutics Corp has made significant progress in its preclinical studies for SIL-204, a siRNA candidate aimed at treating KRAS-driven ...

Silexion Therapeutics Corp, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, announced it has completed an expanded development plan for its ...

Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA ...